Home › Funds › Vestal Point Capital, LP › BBIO
Vestal Point Capital, LP position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Vestal Point Capital, LP reported holding 400,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$26.3M, representing 0.68% of its reported portfolio and ranking #25 among its reported holdings. Vestal Point Capital, LP first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's BBIO position evolved
Vestal Point Capital, LP first disclosed a stake in BBIO in Q3 2026 at 400,000 shares (US$26.3M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 400.00K | $26.32M | New |
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 40 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$957.7M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 14.56M sh · $957.70M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.25M sh · $937.45M · Q3 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.79M sh · $644.33M · Q3 2026
- Two Sigma Investments 3.66M sh · $240.83M · Q3 2026
- Aisling Capital Management LP 3.09M sh · $203.30M · Q3 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 104.89M sh · $162.63M · Q3 2026
- Paradigm Biocapital Advisors LP 2.35M sh · $154.49M · Q3 2026
- SC US (TTGP), LTD. 1.86M sh · $122.41M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.39M sh · $91.65M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held BBIO?
Vestal Point Capital, LP has disclosed BBIO holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Vestal Point Capital, LP's current position in BBIO?
As of Q3 2026, Vestal Point Capital, LP holds 400.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $26.32M, representing 0.68% of its reported portfolio and ranking #25.
Has Vestal Point Capital, LP been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP newly opened its position in BBIO.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.